OBJECTIVES: To investigate the dynamic change of follicular T helper cells (TFH) in patients with malignant lymphoid disease (MLD) and to explore its clinical significance. METHODS: The dynamic change of TFH cells, ICOS+- and PD-1+ TFH cells at pretreatment and different treatment periods was determined by flow cytometry in 85 MLD patients. Concentration of interleukin 21 (IL-21) was evaluated by ELISA, and the correlation between clinical prognosis and the ratio of TFH cells was analyzed. RESULTS: Significantly increased ICOS+- and PD-1+ TFH cells were found in MLD patients at pretreatment compared to healthy controls. Decreased or even close to normal levels of ICOS+- and PD-1+ TFH cells were found at the end of treatment. However, in the patients with progressive disease, high levels of ICOS+- and PD-1+ TFH cells were found. Moreover, a significantly increased plasma IL-21 level was found in MLD patients. Negative correlation was found between the level of ICOS+-, PD-1+ TFH cells, as well as IL-21 and the prognosis of MLD. CONCLUSIONS: Significantly increased TFH cell ratios were found in patients with MLD, and decreased TFH cells ratios could be expected in those treatment-effective patients, which could be used as the therapeutic efficacy index.
OBJECTIVES: To investigate the dynamic change of follicular T helper cells (TFH) in patients with malignant lymphoid disease (MLD) and to explore its clinical significance. METHODS: The dynamic change of TFH cells, ICOS+- and PD-1+ TFH cells at pretreatment and different treatment periods was determined by flow cytometry in 85 MLDpatients. Concentration of interleukin 21 (IL-21) was evaluated by ELISA, and the correlation between clinical prognosis and the ratio of TFH cells was analyzed. RESULTS: Significantly increased ICOS+- and PD-1+ TFH cells were found in MLDpatients at pretreatment compared to healthy controls. Decreased or even close to normal levels of ICOS+- and PD-1+ TFH cells were found at the end of treatment. However, in the patients with progressive disease, high levels of ICOS+- and PD-1+ TFH cells were found. Moreover, a significantly increased plasma IL-21 level was found in MLDpatients. Negative correlation was found between the level of ICOS+-, PD-1+ TFH cells, as well as IL-21 and the prognosis of MLD. CONCLUSIONS: Significantly increased TFH cell ratios were found in patients with MLD, and decreased TFH cells ratios could be expected in those treatment-effective patients, which could be used as the therapeutic efficacy index.
Authors: Neus Serrat; Martina Guerrero-Hernández; Alba Matas-Céspedes; Anella Yahiaoui; Juan G Valero; Ferran Nadeu; Guillem Clot; Miriam Di Re; Marc Corbera-Bellalta; Laura Magnano; Alfredo Rivas-Delgado; Anna Enjuanes; Silvia Beà; Maria C Cid; Elías Campo; Joan Montero; Daniel J Hodson; Armando López-Guillermo; Dolors Colomer; Stacey Tannheimer; Patricia Pérez-Galán Journal: Blood Adv Date: 2020-09-08
Authors: Sofie L M Blokland; Fréderique M van Vliet-Moret; Maarten R Hillen; Aridaman Pandit; Roel Goldschmeding; Aike A Kruize; Gerben Bouma; André van Maurik; Sven Olek; Ulrich Hoffmueller; Joel A G van Roon; Timothy R D J Radstake Journal: Rheumatology (Oxford) Date: 2020-02-01 Impact factor: 7.580
Authors: Inna Serganova; Sanjukta Chakraborty; Samuel Yamshon; Yusuke Isshiki; Ryan Bucktrout; Ari Melnick; Wendy Béguelin; Roberta Zappasodi Journal: Front Cell Dev Biol Date: 2022-01-07
Authors: Victoria Menéndez; José L Solórzano; Sara Fernández; Carlos Montalbán; Juan F García Journal: Cancers (Basel) Date: 2022-03-07 Impact factor: 6.639